All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Favipiravir
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Appili Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership May 11, 2020
Details:
Appili Therapeutics to sponsor first clinical program in the world designed to assess the use of FUJIFILM Toyama Chemical’s favipiravir for COVID-19 as prophylaxis for outbreak control.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): HLCM051
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 14, 2020
Details:
HEALIOS K.K continues to make enrolment progress in its ONE-BRIDGE study, a phase II clinical trial in Japan evaluating the safety and efficacy of HLCM051.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
